These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32132978)

  • 1. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
    Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
    Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
    [No Abstract]   [Full Text] [Related]  

  • 2. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
    Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
    Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline
    Alzahrani AS; Bin Nafisah A; Alswailem M; Moria Y; Poprawski D; Al-Hindi H; Pacak K
    Front Endocrinol (Lausanne); 2023; 14():1273093. PubMed ID: 38152133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
    Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
    Mathur R; Zhang Y; Grimmer MR; Hong C; Zhang M; Bollam S; Petrecca K; Clarke J; Berger MS; Phillips JJ; Oberheim-Bush NA; Molinaro AM; Chang SM; Costello JF
    Neuro Oncol; 2020 Nov; 22(11):1580-1590. PubMed ID: 32166314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
    Ferrara AM; Lombardi G; Pambuku A; Meringolo D; Bertorelle R; Nardin M; Schiavi F; Iacobone M; Opocher G; Zagonel V; Zovato S
    Anticancer Drugs; 2018 Jan; 29(1):102-105. PubMed ID: 29099418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT protein expression is a reliable predictive biomarker for temozolomide-containing chemotherapy in osteosarcoma.
    Uchihara Y; Umeda K; Yamada Y; Ito H; Tasaka K; Isobe K; Akazawa R; Kawabata N; Saida S; Kato I; Hiramatsu H; Noguchi T; Sakamoto A; Arakawa Y; Arakawa A; Yamamoto N; Hosoya Y; Uemura S; Watanabe KI; Sano H; Taga T; Takita J
    Cancer Sci; 2024 Oct; 115(10):3394-3402. PubMed ID: 39080996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
    Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
    Urquhart C; Fleming B; Harper I; Aloj L; Armstrong R; Hook L; Long AM; Jackson C; Gallagher FA; McLean MA; Tarpey P; Kosmoliaptsis V; Nicholson J; Hendriks AEJ; Casey RT
    Front Endocrinol (Lausanne); 2022; 13():1066208. PubMed ID: 36440187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation.
    Cui Y; Ma X; Wang F; Wang H; Zhou T; Chen S; Tong A; Li Y
    Endocr Pract; 2021 Apr; 27(4):348-353. PubMed ID: 34024343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
    Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
    van Thuijl HF; Mazor T; Johnson BE; Fouse SD; Aihara K; Hong C; Malmström A; Hallbeck M; Heimans JJ; Kloezeman JJ; Stenmark-Askmalm M; Lamfers ML; Saito N; Aburatani H; Mukasa A; Berger MS; Söderkvist P; Taylor BS; Molinaro AM; Wesseling P; Reijneveld JC; Chang SM; Ylstra B; Costello JF
    Acta Neuropathol; 2015 Apr; 129(4):597-607. PubMed ID: 25724300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
    J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
    Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
    Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
    Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
    Wick W; Dettmer S; Berberich A; Kessler T; Karapanagiotou-Schenkel I; Wick A; Winkler F; Pfaff E; Brors B; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Eisenmenger A; von Deimling A; Jones DTW; Pfister SM; Sahm F; Platten M
    Neuro Oncol; 2019 Jan; 21(1):95-105. PubMed ID: 30277538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.